760
edits
Template for risk assessment: Difference between revisions
From London Hackspace Wiki
m
no edit summary
(Created page with "{{RiskAssessment |printiple_investigator=tolland }} This is a test risk assessment") |
mNo edit summary |
||
| Line 2: | Line 2: | ||
|printiple_investigator=tolland | |printiple_investigator=tolland | ||
}} | }} | ||
This is a | |||
{|- | |||
|created||17 June 2014 | |||
|- | |||
|updated||17 June 2014 | |||
|- | |||
|approved date||NA | |||
|- | |||
|status||Template | |||
|} | |||
== Description of Project == | |||
Routine cloning and manipulation of harmless eukaryotic sequences in disabled E. coli K12 strains using non-mobilisable and/or mobilisation-defective vectors, with no intention to express gene products. | |||
== Location of Work == | |||
The GM activity with take place in the London Hackspace biolab at 447 Hackney Road, London, E2 9DY | |||
The laboratory work will be done at CL-1 | |||
There will be no animal work | |||
== Principal Investigator == | |||
Tom Hodder | |||
== Other Personnel == | |||
Sam Thompson | |||
== Description of the project, including the methods to be used and the purpose of the genetic modification == | |||
This is a generic risk assessment for cloning harmless sequences from any eukaryotic organism into disabled E. coli K12 hosts for the purpose of facilitating molecular biology procedures such as (i) sub-cloning, DNA sequencing, or site-directed mutagenesis; (ii) construction of fusions with harmless reporter genes such as GFP; (iii) construction of recombinant plasmids for subsequent transfection of eukaryotic cell lines; (iv) construction of recombinant plasmids for subsequent transfection of defined packaging cell lines for the purpose of producing disabled recombinant viral vectors. [Note: in examples (iii) and (iv), the subsequent transfection experiments will need to be covered by separate, specific risk assessments]. | |||
This risk assessment specifically excludes cloning sequences that are known or suspected to: | |||
(i) be oncogenic; | |||
or (ii) encode either a toxin or an allergen; | |||
or (iii) encode a product that could have detrimental effect if delivered to a target tissue. | |||
[Note: cloning any of the above types of excluded sequences will need to be covered by non-generic, specific risk assessments.]. | |||
